Press release
Familial Lipoprotein Lipase Deficiency Market to Reflect a Holistic Expansion with Highest CAGR by 2031 | Ionis Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., Aetna Inc.
Familial Lipoprotein Lipase Deficiency Market || 2024-2031
DataM Intelligence has published a new research report on "Familial Lipoprotein Lipase Deficiency Market Size 2024". The report explores comprehensive and insightful Information about various key factors like Segmentation, CAGR, business revenue competitive positioning of key companies, investigating elements such as product offerings, pricing strategies, financial performance, product portfolios, growth initiatives, and geographical reach. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.
Get a Free Sample Research PDF - https://datamintelligence.com/download-sample/familial-lipoprotein-lipase-deficiency-market
The Familial Lipoprotein Lipase Deficiency (LPLD) Market refers to the segment of the healthcare industry focused on the diagnosis, treatment, and management of familial lipoprotein lipase deficiency, a rare genetic disorder characterized by the inability to effectively break down triglycerides due to a deficiency in the enzyme lipoprotein lipase. This condition can lead to severe hypertriglyceridemia, resulting in recurrent episodes of abdominal pain, pancreatitis, and potential cardiovascular complications. The market encompasses a range of therapies, including enzyme replacement therapies, gene therapies, dietary management, and supportive treatments aimed at improving patient outcomes and quality of life.
Key Developments:
In December 2023, Ultragenyx Pharmaceutical Inc. announced that the European Commission (EC) has expanded the approval of Evkeeza as an adjunct to diet and other lipid-lowering therapies for the treatment of children aged 5 to 11 years with homozygous familial hypercholesterolemia (HoFH). This makes Evkeeza the first treatment that specifically inhibits angiopoietin-like 3 (ANGPTL3) indicated for children as young as 5 to manage dangerously high levels of low-density lipoprotein cholesterol (LDL-C) associated with HoFH.
Earlier, in March 2023, Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) had also expanded the approval of Evkeeza for use as an adjunct to other lipid-lowering therapies for treating children aged 5 to 11 with HoFH. This marked Evkeeza as the first ANGPTL3 inhibitor approved for this age group to manage dangerously high LDL-C levels linked to HoFH.
Research Process:
Both primary and secondary data sources have been used in the global Familial Lipoprotein Lipase Deficiency Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
List of the Key Players in the Familial Lipoprotein Lipase Deficiency Market:
Ionis Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., Aetna Inc., Ultragenyx Pharmaceutical Inc., Arrowhead Pharmaceuticals Inc., MANUS AKTTEVA BIOPHARMA LLP, Silverline Chemicals, Sainor, GSK plc, and PTC Therapeutics.
Segment Covered in the Familial Lipoprotein Lipase Deficiency Market:
By Treatment Type: Olezarsen, Evinacumab, Orlistat, Alipogene Tiparvovec.
By Age Group: 1-10 Years, 13-60 Years.
By Gender: Male, Female.
By End-User: Hospitals & Specialty Clinics, Ambulatory Surgical Centers, Others.
Regional Analysis:
The global Familial Lipoprotein Lipase Deficiency Market report focuses on six major regions: North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa.
Get Customization in the report as per your requirements: https://datamintelligence.com/customize/familial-lipoprotein-lipase-deficiency-market
Regional Analysis:
The global Familial Lipoprotein Lipase Deficiency Market report focuses on six major regions: North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa. The report offers detailed insight into new product launches, new technology evolutions, innovative services, and ongoing R&D. The report discusses a qualitative and quantitative market analysis, including PEST analysis, SWOT analysis, and Porter's five force analysis. The Familial Lipoprotein Lipase Deficiency Market report also provides fundamental details such as raw material sources, distribution networks, methodologies, production capacities, industry supply chain, and product specifications.
**The full version of the report includes an in-depth analysis of emerging players and startups, which will provide valuable insights into the evolving market landscape and key strategies being adopted**
Chapter Outline:
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: key insights, key emerging trends, etc.
Chapter 3: Manufacturers competitive analysis, detailed analysis of Familial Lipoprotein Lipase Deficiency manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 5 & 6: Revenue of Familial Lipoprotein Lipase Deficiency in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: The main points and conclusions of the report.
Have any Query? Talk to our Expert @ https://www.datamintelligence.com/enquiry/familial-lipoprotein-lipase-deficiency-market
Frequently Asked Questions
Q1) Who are the key players of Familial Lipoprotein Lipase Deficiency Market?
A) Key players are Ionis Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., Aetna Inc., Ultragenyx Pharmaceutical Inc., Arrowhead Pharmaceuticals Inc., MANUS AKTTEVA BIOPHARMA LLP, Silverline Chemicals, Sainor, GSK plc, and PTC Therapeutics.
Q2) What are the regions covered in this report?
A) The global Familial Lipoprotein Lipase Deficiency Market report focuses on six major regions: North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa
3) What are the Segments Coverd in this report?
A) The Familial Lipoprotein Lipase Deficiency market is segmented as
By Treatment Type: Olezarsen, Evinacumab, Orlistat, Alipogene Tiparvovec.
By Age Group: 1-10 Years, 13-60 Years.
By Gender: Male, Female.
By End-User: Hospitals & Specialty Clinics, Ambulatory Surgical Centers, Others.
Read Latest Blog: https://www.datamintelligence.com/blogs/top-10-process-automation-companies-worldwide
Affiliate Marketing Request here: https://www.datamintelligence.com/affiliate-marketing
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Familial Lipoprotein Lipase Deficiency Market to Reflect a Holistic Expansion with Highest CAGR by 2031 | Ionis Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., Aetna Inc. here
News-ID: 3674547 • Views: …
More Releases from DataM Intelligence 4Market Research
United States Tobacco Testing Market Set for Strong Growth Amid Rising Health Re …
Market Overview:
The Tobacco Testing Market is estimated to reach at a CAGR of 4% during the forecast period 2024-2031.
The Tobacco Testing Market report by DataM Intelligence provides insights into the latest trends and developments in the market. This report identifies the key growth opportunities in the market and provides recommendations for market participants to capitalize on these opportunities. Overall, the Tobacco Testing market report is an essential resource for market…
United States Refractory Metals Market Set for Strong Growth Driven by High-Temp …
Market Overview:
The Refractory Metals Market is growing at a CAGR of 1.8% during the forecast period 2024-2031.
The Refractory Metals Market report by DataM Intelligence provides insights into the latest trends and developments in the market. This report identifies the key growth opportunities in the market and provides recommendations for market participants to capitalize on these opportunities. Overall, the Refractory Metals market report is an essential resource for market participants who…
United States Alternative Proteins Market Set for Explosive Growth: Driving Sust …
Market Size and Growth:
The Global Alternative Proteins Market Size was valued at US$ 25.7 Billion in 2022 and is expected to reach USD 81.9 Billion by 2031, exhibiting a CAGR of 15.6% during the forecast period (2025-2032)
The Alternative Proteins Market report by DataM Intelligence provides insights into the latest trends and developments in the market. This report identifies the key growth opportunities in the market and provides recommendations for market…
United States Meat Alternatives Market Surges as Consumers Embrace Plant-Based & …
Market Size and Growth:
The Global Meat Alternatives Market size value was USD 9.6 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 20.8 billion by 2031. The market is growing at a CAGR of 10.2% during the forecast period 2024-2031.
The Meat Alternatives Market report by DataM Intelligence provides insights into the latest trends and developments in the market. This report identifies the key growth…
More Releases for Familial
Homozygous Familial Hypercholesterolemia (HoFH) Market Massive Growth opportunit …
Introduction
Homozygous Familial Hypercholesterolemia (HoFH) is a rare genetic lipid disorder characterized by extremely high low-density lipoprotein cholesterol (LDL-C) levels from birth, often exceeding 500 mg/dL. Caused by mutations in both alleles of the LDLR, APOB, or PCSK9 genes, HoFH leads to early-onset atherosclerosis, cardiovascular disease, and premature mortality if untreated.
Historically, management relied on lipid-lowering agents, LDL apheresis, and lifestyle modifications. However, the last decade has witnessed a paradigm shift with…
Familial Adenomatous Polyposis (FAP) Therapeutics- Pipeline Analysis 2018
Familial adenomatous polyposis (FAP) is a genetic disorder, characterized by the development of adenomatous colon polyps in the intestinal tract, resulting in colon cancer. The disease is diagnosed when more than 100 adenomatous colon polyps are developed in a person.
Download the sample report at: https://www.pharmaproff.com/request-sample/1025
A person with FAP is at a high risk of developing cancer of small intestines or stomach. This disease is categorized into three types including attenuated…
Heterozygous Familial Hypercholesterolemia (heFH) Therapeutics - Pipeline Analys …
Heterozygous familial hypercholesterolemia (HeFH) is an inherited genetic disorder that affects the body’s ability to control cholesterol. It is characterized by very high LDL (low density lipoprotein) cholesterol (above 190 for adults or above 160 for children) and family history of high cholesterol, heart disease or stroke.
Download the sample report @ https://www.pharmaproff.com/request-sample/1135
A very high level of LDL from birth leads to a twenty-fold increase in the risk of premature…
Familial Amyloid Cardiomyopathy Treatment Market Opportunity Analysis, 2018–20 …
Aggregation and deposition of mutant and wild-type transthyretin protein (TTR) in heart results in familial amyloid cardiomyopathy, which typically occur after age of 60. Familial amyloid cardiomyopathy is also known as hereditary cardiac transthyretin amyloidosis or hereditary amyloid cardiomyopathy. The protein transthyretin amyloid fibrils infiltrate the myocardium that leads to diastolic dysfunction from restrictive cardiomyopathy, which eventually result to heart failure. There are several mutation in TTR which are associated…
Familial Adenomatous Polyposis Pipeline Therapeutics Development Market Review 2 …
RnRMarketResearch.com adds “Familial Adenomatous Polyposis - Pipeline Review, H1 2017” to its store providing an overview of the Familial Adenomatous Polyposis therapeutic pipeline with comprehensive information on the therapeutic development for Familial Adenomatous Polyposis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews…
Familial Adenomatous Polyposis - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Familial Adenomatous Polyposis - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Familial Adenomatous Polyposis - Pipeline Review, H1 2017, provides an overview of the Familial Adenomatous Polyposis (Genetic Disorders) pipeline landscape.
Familial adenomatous polyposis (FAP) is also known as familial polyposis coli, adenomatous polyposis coli, or…
